Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of AVP-786 for agitation in Alzheimer's disease dementia
2017-002455-29Phase 3Completed
- Sponsor
- Avanir Pharmaceuticals
- Start
- May 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of deudextromethorphan in Alzheimer's disease (AD), sponsored by Avanir Pharmaceuticals. Primary endpoint: Safety and tolerability of AVP-786. Started May 2018; status: completed.
02
Drugs
deudextromethorphan
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2017-002455-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002455-29.